Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Camrelizumab plus apatinib and SOX as first-line treatment in patients with alpha-fetoprotein–producing gastric or gastroesophageal junction adenocarcinoma: A single-arm, multi-center, phase 2 trial.
Authors
Yakun Wang
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, HaiDian District, Beijing, Beijing, China
Yakun Wang , Chang Wang , Xiaofeng Chen , Zhi Peng , Yanhong Gu , Yizhuo Wang , Xicheng Wang , Jian Li , Jifang Gong , Changsong Qi , Jiajia Yuan , Zhihao Lu , Ming Lu , Lin Shen , Yanshuo Cao , Lin Shen , Xiaotian Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04609176
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 351)
DOI
10.1200/JCO.2024.42.3_suppl.351
Abstract #
351
Poster Bd #
G12
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Camrelizumab plus low-dose apatinib and SOX in the first-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: A single-arm, dose escalation and expansion study (SPACE study).
First Author: Xiaofeng Chen
Poster
2022 ASCO Annual Meeting
Camrelizumab plus apatinib as induction therapy for locally advanced head and neck squamous cell carcinoma (IMplus): A single-arm phase II study.
First Author: Lulu Ye
Poster
2022 ASCO Annual Meeting
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
First Author: Huaying Wang
Poster
2022 ASCO Annual Meeting
Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage c: A prospective, single-arm, phase II trial (TRIPLET study).
First Author: Yang-Kui Gu